Review Article Open Access

Review on Synthetic Approaches and Reported Polymorphs for Pazopanib Hydrochloride (Votrient), an Anticancer Drug

Abstract

Cancer advert to rapid and uncontrolled growth of cells which expand to different parts of the body through blood or lymph and the drugs which inhibits the abnormal growth of cells or kill the cancer cells are known as anti-cancer drugs. In the recent years, there is a remarkable growth in the development of anticancer drugs. This article reviews the literature on synthetic routes and different polymorphic forms of one of the anti-cancer drug named “VOTRIENT (Pazopanib)” a Tyrosine Kinase Inhibitor (TKI). A systematic review of different articles, patents, and official assessment reports of different agencies shows that Novartis is the inventor of Pazopanib drug substance, and its route of synthesis consists of mainly four steps starting from 3-methyl-6-nitro-1H-indazole. The marketed polymorphic form of Pazopanib hydrochloride prepared by inventor is anhydrous crystalline polymorphic form 1. This review gives an insight of different existing route of synthesis and polymorphic forms of Pazopanib and its different reported salts.

Onkar Chand*, Lalita Chopra, Shashi Kant Tiwari

To read the full article Download Full Article